Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2009

Open Access 01-12-2009 | Review

Unique aspects of transcriptional regulation in neurons – nuances in NFκB and Sp1-related factors

Authors: Xianrong R Mao, Andréa M Moerman-Herzog, Yuzhi Chen, Steven W Barger

Published in: Journal of Neuroinflammation | Issue 1/2009

Login to get access

Abstract

The unique physiology and function of neurons create differences in their cellular physiology, including their regulation of gene expression. We began several years ago exploring the relationships between the NFκB transcription factor, neuronal survival, and glutamate receptor activation in telencephalic neurons. These studies led us to conclude that this population of cells is nearly incapable of activating the NFκB that is nonetheless expressed at reasonable levels. A subset of the κB cis elements are instead bound by members of the Sp1 family in neurons. Also surprising was our discovery that Sp1 itself, typically described as ubiquitous, is severely restricted in expression within forebrain neurons; Sp4 seems to be substituted during neuronal differentiation. These findings and their implications for neuronal differentiation – as well as potential dedifferentiation during degenerative processes – are discussed here.
Appendix
Available only for authorised users
Literature
1.
Siebenlist U, Franzoso G, Brown K: Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol. 1994, 10: 405-55. 10.1146/annurev.cb.10.110194.002201.CrossRefPubMed
2.
Massa PE, Aleyasin H, Park DS, Mao X, Barger SW: NFkB in neurons? The uncertainty principle in neurobiology. J Neurochem. 2006, 97: 607-618. 10.1111/j.1471-4159.2006.03810.x.PubMedCentralCrossRefPubMed
3.
Saccani S, Marazzi I, Beg AA, Natoli G: Degradation of promoter-bound p65/RelA is essential for the prompt termination of the nuclear factor kappaB response. J Exp Med. 2004, 200: 107-13. 10.1084/jem.20040196.PubMedCentralCrossRefPubMed
4.
5.
Qiu J, Grafe MR, Schmura SM, Glasgow JN, Kent TA, Rassin DK, Perez-Polo JR: Differential NF-kappa B regulation of bcl-x gene expression in hippocampus and basal forebrain in response to hypoxia. J Neurosci Res. 2001, 64: 223-34. 10.1002/jnr.1070.CrossRefPubMed
6.
Jiang HY, Petrovas C, Sonenshein GE: RelB-p50 NF-kappa B complexes are selectively induced by cytomegalovirus immediate-early protein 1: differential regulation of Bcl-x(L) promoter activity by NF-kappa B family members. J Virol. 2002, 76: 5737-47. 10.1128/JVI.76.11.5737-5747.2002.PubMedCentralCrossRefPubMed
7.
Krikos A, Laherty CD, Dixit VM: Transcriptional activation of the tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by kappa B elements. J Biol Chem. 1992, 267: 17971-6.PubMed
8.
Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C: The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev. 1999, 13: 382-7. 10.1101/gad.13.4.382.PubMedCentralCrossRefPubMed
9.
Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW: Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci USA. 1997, 94: 10057-62. 10.1073/pnas.94.19.10057.PubMedCentralCrossRefPubMed
10.
Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC, Karin M: Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science. 2001, 293: 1495-9. 10.1126/science.1062677.CrossRefPubMed
11.
Lawrence T, Bebien M, Liu GY, Nizet V, Karin M: IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature. 2005, 434: 1138-43. 10.1038/nature03491.CrossRefPubMed
12.
Lipton SA, Rosenberg PA: Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med. 1994, 330: 613-22. 10.1056/NEJM199403033300907.CrossRefPubMed
13.
14.
Kaltschmidt C, Kaltschmidt B, Baeuerle PA: Stimulation of ionotropic glutamate receptors activates transcription factor NF-kB in primary neurons. Proc Natl Acad Sci USA. 1995, 92: 9618-9622. 10.1073/pnas.92.21.9618.PubMedCentralCrossRefPubMed
15.
Guerrini L, Blasi F, Denis-Donini S: Synaptic activation of NF-kB by glutamate in cerebellar granule neurons in vitro. Proc Natl Acad Sci USA. 1995, 92: 9077-9081. 10.1073/pnas.92.20.9077.PubMedCentralCrossRefPubMed
16.
Seil FJ, Drake-Baumann R, Herndon RM, Leiman AL: Cytosine arabinoside effects in mouse cerebellar cultures in the presence of astrocytes. Neuroscience. 1992, 51: 149-58. 10.1016/0306-4522(92)90479-L.CrossRefPubMed
17.
Dessi F, Pollard H, Moreau J, Ben-Ari Y, Charriaut-Marlangue C: Cytosine arabinoside induces apoptosis in cerebellar neurons in culture. J Neurochem. 1995, 64: 1980-7.CrossRefPubMed
18.
van't Land B, Blijlevens NM, Marteijn J, Timal S, Donnelly JP, de Witte TJ, M'Rabet L: Role of curcumin and the inhibition of NF-kappaB in the onset of chemotherapy-induced mucosal barrier injury. Leukemia. 2004, 18: 276-84. 10.1038/sj.leu.2403233.CrossRefPubMed
19.
Sreenivasan Y, Sarkar A, Manna SK: Mechanism of cytosine arabinoside-mediated apoptosis: role of Rel A (p65) dephosphorylation. Oncogene. 2003, 22: 4356-69. 10.1038/sj.onc.1206486.CrossRefPubMed
20.
Barger SW, Moerman AM, Mao X: Molecular mechanisms of cytokine-induced neuroprotection: NFkappaB and neuroplasticity. Curr Pharm Des. 2005, 11: 985-98. 10.2174/1381612053381594.CrossRefPubMed
21.
Mukaida N, Morita M, Ishikawa Y, Rice N, Okamoto S, Kasahara T: Novel mechanism of glucocorticoid-mediated gene repression. Nuclear factor-kB is target for glucocorticoid-mediated interleukin 8 gene repression. J Biol Chem. 1994, 269: 13289-13295.PubMed
22.
Brostjan C, Anrather J, Csizmadia V, Stroka D, Soares M, Bach FH, Winkler H: Glucocorticoid-mediated repression of NFkappaB activity in endothelial cells does not involve induction of IkappaBalpha synthesis. J Biol Chem. 1996, 271: 19612-6. 10.1074/jbc.271.32.19612.CrossRefPubMed
23.
Ray KP, Farrow S, Daly M, Talabot F, Searle N: Induction of the E-selectin promoter by interleukin 1 and tumour necrosis factor alpha, and inhibition by glucocorticoids. Biochem J. 1997, 328 (Pt 2): 707-15.PubMedCentralCrossRefPubMed
24.
Harant H, Wolff B, Lindley IJ: 1Alpha,25-dihydroxyvitamin D3 decreases DNA binding of nuclear factor-kappaB in human fibroblasts. FEBS Lett. 1998, 436: 329-34. 10.1016/S0014-5793(98)01153-3.CrossRefPubMed
25.
Wang D, Baldwin AS: Activation of nuclear factor-kappaB-dependent transcription by tumor necrosis factor-alpha is mediated through phosphorylation of RelA/p65 on serine 529. J Biol Chem. 1998, 273: 29411-6. 10.1074/jbc.273.45.29411.CrossRefPubMed
26.
Liden J, Rafter I, Truss M, Gustafsson JA, Okret S: Glucocorticoid effects on NF-kappaB binding in the transcription of the ICAM-1 gene. Biochem Biophys Res Commun. 2000, 273: 1008-14. 10.1006/bbrc.2000.3079.CrossRefPubMed
27.
True AL, Rahman A, Malik AB: Activation of NF-kappaB induced by H(2)O(2) and TNF-alpha and its effects on ICAM-1 expression in endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2000, 279: L302-11.PubMed
28.
Leitges M, Sanz L, Martin P, Duran A, Braun U, Garcia JF, Camacho F, Diaz-Meco MT, Rennert PD, Moscat J: Targeted disruption of the zetaPKC gene results in the impairment of the NF-kappaB pathway. Mol Cell. 2001, 8: 771-80. 10.1016/S1097-2765(01)00361-6.CrossRefPubMed
29.
Din FV, Stark LA, Dunlop MG: Aspirin-induced nuclear translocation of NFkappaB and apoptosis in colorectal cancer is independent of p53 status and DNA mismatch repair proficiency. Br J Cancer. 2005, 92: 1137-43. 10.1038/sj.bjc.6602455.PubMedCentralCrossRefPubMed
30.
Mao X, Moerman AM, Lucas MM, Barger SW: Inhibition of the activity of a neuronal kB-binding factor (NKBF) by glutamate. J Neurochem. 1999, 73: 1851-1858.PubMed
31.
Moerman AM, Mao X, Lucas MM, Barger SW: Characterization of a neuronal kB-binding factor distinct from NF-kB. Mol Brain Res. 1999, 67: 303-315. 10.1016/S0169-328X(99)00091-1.CrossRefPubMed
32.
Mao X, Moerman AM, Barger SW: Neuronal kB-binding factors consist of Sp1-related proteins: Functional implications for autoregulation of NR1 expression. J Biol Chem. 2002, 277: 44911-44919. 10.1074/jbc.M204292200.CrossRefPubMed
33.
Bhakar AL, Tannis LL, Zeindler C, Russo MP, Jobin C, Park DS, MacPherson S, Barker PA: Constitutive nuclear factor-kappa B activity is required for central neuron survival. J Neurosci. 2002, 22: 8466-75.PubMed
34.
Fridmacher V, Kaltschmidt B, Goudeau B, Ndiaye D, Rossi FM, Pfeiffer J, Kaltschmidt C, Israel A, Memet S: Forebrain-specific neuronal inhibition of nuclear factor-kappaB activity leads to loss of neuroprotection. J Neurosci. 2003, 23: 9403-8.PubMed
35.
Yurochko AD, Mayo MW, Poma EE, Baldwin AS, Huang ES: Induction of the transcription factor Sp1 during human cytomegalovirus infection mediates upregulation of the p65 and p105/p50 NF-kappaB promoters. J Virol. 1997, 71: 4638-48.PubMedCentralPubMed
36.
Schmidt-Ullrich R, Mémet S, Lilienbaum A, Feuillard J, Raphael M, Israël A: NF-kB activity in transgenic mice: developmental regulation and tissue specificity. Development. 1996, 122: 2117-2128.PubMed
37.
Heckman CA, Mehew JW, Boxer LM: NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene. 2002, 21: 3898-908. 10.1038/sj.onc.1205483.CrossRefPubMed
38.
Jarosinski KW, Whitney LW, Massa PT: Specific deficiency in nuclear factor-kB activation in neurons of the central nervous system. Lab Invest. 2001, 81: 1275-1288. 10.1038/labinvest.3780341.CrossRefPubMed
39.
Saha RN, Pahan K: Greater availability of NF-kB p65:p50 in glia than neurons: implications for neurodegenerative disorders. J Neurochem. 2005, 94: S127-10.1111/j.1474-1644.2005.03231_10.x.CrossRef
40.
Kaltschmidt B, Kaltschmidt C: Constitutive NF-kappa B activity is modulated via neuron-astroglia interaction. Exp Brain Res. 2000, 130: 100-4. 10.1007/s002210050011.CrossRefPubMed
41.
Peterson C, Neal JH, Cotman CW: Development of N-methyl-D-aspartate excitotoxicity in cultured hippocampal neurons. Brain Res Dev Brain Res. 1989, 48: 187-95. 10.1016/0165-3806(89)90075-8.CrossRefPubMed
42.
Li Q, Verma IM: NF-kappaB regulation in the immune system. Nat Rev Immunol. 2002, 2: 725-34. 10.1038/nri910.CrossRefPubMed
43.
Narayanan R, Klement JF, Ruben SM, Higgins KA, Rosen CA: Identification of a naturally occurring transforming variant of the p65 subunit of NF-kappa B. Science. 1992, 256: 367-70. 10.1126/science.256.5055.367.CrossRefPubMed
44.
Ruben SM, Narayanan R, Klement JF, Chen CH, Rosen CA: Functional characterization of the NF-kappa B p65 transcriptional activator and an alternatively spliced derivative. Mol Cell Biol. 1992, 12: 444-54.PubMedCentralCrossRefPubMed
45.
Deloukas P, van Loon AP: Genomic organization of the gene encoding the p65 subunit of NF-kappa B: multiple variants of the p65 protein may be generated by alternative splicing. Hum Mol Genet. 1993, 2: 1895-900. 10.1093/hmg/2.11.1895.CrossRefPubMed
46.
Maxwell SA, Mukhopadhyay T: A novel NF-kappa B p65 spliced transcript lacking exons 6 and 7 in a non-small cell lung carcinoma cell line. Gene. 1995, 166: 339-40. 10.1016/0378-1119(95)00578-1.CrossRefPubMed
47.
Trecca D, Guerrini L, Fracchiolla NS, Pomati M, Baldini L, Maiolo AT, Neri A: Identification of a tumor-associated mutant form of the NF-kappaB RelA gene with reduced DNA-binding and transactivating activities. Oncogene. 1997, 14: 791-9. 10.1038/sj.onc.1200895.CrossRefPubMed
48.
Meffert MK, Chang JM, Wiltgen BJ, Fanselow MS, Baltimore D: NF-kappa B functions in synaptic signaling and behavior. Nat Neurosci. 2003, 6: 1072-8. 10.1038/nn1110.CrossRefPubMed
49.
Krappmann D, Scheidereit C: A pervasive role of ubiquitin conjugation in activation and termination of IkappaB kinase pathways. EMBO Rep. 2005, 6: 321-6. 10.1038/sj.embor.7400380.PubMedCentralCrossRefPubMed
50.
Mao X, Moerman-Herzog AM, Wang W, Barger SW: Differential transcriptional control of the superoxide dismutase-2 kappaB element in neurons and astrocytes. J Biol Chem. 2006, 281: 35863-72. 10.1074/jbc.M604166200.PubMedCentralCrossRefPubMed
51.
Mao X, Yang SH, Simpkins JW, Barger SW: Glutamate receptor activation evokes calpain-mediated degradation of Sp3 and Sp4, the prominent Sp-family transcription factors in neurons. J Neurochem. 2007, 100: 1300-14. 10.1111/j.1471-4159.2006.04297.x.PubMedCentralCrossRefPubMed
52.
Bradley JR, Pober JS: Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene. 2001, 20: 6482-91. 10.1038/sj.onc.1204788.CrossRefPubMed
53.
Speir E, Yu ZX, Takeda K, Ferrans VJ, Cannon RO: Competition for p300 regulates transcription by estrogen receptors and nuclear factor-kappaB in human coronary smooth muscle cells. Circ Res. 2000, 87: 1006-11.CrossRefPubMed
54.
Chen LF, Mu Y, Greene WC: Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. Embo J. 2002, 21: 6539-48. 10.1093/emboj/cdf660.PubMedCentralCrossRefPubMed
55.
Sasaki CY, Barberi TJ, Ghosh P, Longo DL: Phosphorylation of RelA/p65 on serine 536 defines an IκBα-independent NF-κB pathway. J Biol Chem. 2005, 280: 34538-47. 10.1074/jbc.M504943200.CrossRefPubMed
56.
Hou S, Guan H, Ricciardi RP: Phosphorylation of serine 337 of NF-kappaB p50 is critical for DNA binding. J Biol Chem. 2003, 278: 45994-8. 10.1074/jbc.M307971200.CrossRefPubMed
57.
Anrather J, Racchumi G, Iadecola C: cis-acting, element-specific transcriptional activity of differentially phosphorylated nuclear factor-kappa B. J Biol Chem. 2005, 280: 244-52.CrossRefPubMed
58.
Duran A, Diaz-Meco MT, Moscat J: Essential role of RelA Ser311 phosphorylation by zetaPKC in NF-kappaB transcriptional activation. Embo J. 2003, 22: 3910-8. 10.1093/emboj/cdg370.PubMedCentralCrossRefPubMed
59.
60.
Marienfeld R, May MJ, Berberich I, Serfling E, Ghosh S, Neumann M: RelB forms transcriptionally inactive complexes with RelA/p65. J Biol Chem. 2003, 278: 19852-60. 10.1074/jbc.M301945200.CrossRefPubMed
61.
62.
Suske G, Bruford E, Philipsen S: Mammalian SP/KLF transcription factors: bring in the family. Genomics. 2005, 85: 551-6. 10.1016/j.ygeno.2005.01.005.CrossRefPubMed
63.
Hirano F, Tanaka H, Hirano Y, Hiramoto M, Handa H, Makino I, Scheidereit C: Functional interference of Sp1 and NF-kappaB through the same DNA binding site. Mol Cell Biol. 1998, 18: 1266-74.PubMedCentralCrossRefPubMed
64.
Hagen G, Dennig J, Preiss A, Beato M, Suske G: Functional analyses of the transcription factor Sp4 reveal properties distinct from Sp1 and Sp3. J Biol Chem. 1995, 270: 24989-94. 10.1074/jbc.270.42.24989.CrossRefPubMed
65.
Wong WK, Chen K, Shih JC: Regulation of human monoamine oxidase B gene by Sp1 and Sp3. Mol Pharmacol. 2001, 59: 852-9.PubMed
66.
Ishimaru N, Tabuchi A, Hara D, Hayashi H, Sugimoto T, Yasuhara M, Shiota J, Tsuda M: Regulation of neurotrophin-3 gene transcription by Sp3 and Sp4 in neurons. J Neurochem. 2007, 100: 520-31. 10.1111/j.1471-4159.2006.04216.x.CrossRefPubMed
67.
Leggett RW, Armstrong SA, Barry D, Mueller CR: Sp1 is phosphorylated and its DNA binding activity down-regulated upon terminal differentiation of the liver. J Biol Chem. 1995, 270: 25879-84. 10.1074/jbc.270.43.25879.CrossRefPubMed
68.
Zwicker J, Gross C, Lucibello FC, Truss M, Ehlert F, Engeland K, Muller R: Cell cycle regulation of cdc25C transcription is mediated by the periodic repression of the glutamine-rich activators NF-Y and Sp1. Nucleic Acids Res. 1995, 23: 3822-30. 10.1093/nar/23.19.3822.PubMedCentralCrossRefPubMed
69.
Innocente SA, Lee JM: p53 is a NF-Y- and p21-independent, Sp1-dependent repressor of cyclin B1 transcription. FEBS Lett. 2005, 579: 1001-7. 10.1016/j.febslet.2004.12.073.CrossRefPubMed
70.
Nagata D, Suzuki E, Nishimatsu H, Satonaka H, Goto A, Omata M, Hirata Y: Transcriptional activation of the cyclin D1 gene is mediated by multiple cis-elements, including SP1 sites and a cAMP-responsive element in vascular endothelial cells. J Biol Chem. 2001, 276: 662-9. 10.1074/jbc.M005522200.CrossRefPubMed
71.
Kim S, Kang JK, Kim YK, Seo DW, Ahn SH, Lee JC, Lee CH, You JS, Cho EJ, Lee HW, Han JW: Histone deacetylase inhibitor apicidin induces cyclin E expression through Sp1 sites. Biochem Biophys Res Commun. 2006, 342: 1168-73. 10.1016/j.bbrc.2006.02.081.CrossRefPubMed
72.
Rotheneder H, Geymayer S, Haidweger E: Transcription factors of the Sp1 family: interaction with E2F and regulation of the murine thymidine kinase promoter. J Mol Biol. 1999, 293: 1005-15. 10.1006/jmbi.1999.3213.CrossRefPubMed
73.
Fojas de Borja P, Collins NK, Du P, Azizkhan-Clifford J, Mudryj M: Cyclin A-CDK phosphorylates Sp1 and enhances Sp1-mediated transcription. Embo J. 2001, 20: 5737-47. 10.1093/emboj/20.20.5737.CrossRefPubMed
74.
Banchio C, Schang LM, Vance DE: Activation of CTP:phosphocholine cytidylyltransferase alpha expression during the S phase of the cell cycle is mediated by the transcription factor Sp1. J Biol Chem. 2003, 278: 32457-64. 10.1074/jbc.M304810200.CrossRefPubMed
75.
Ishibashi H, Nakagawa K, Onimaru M, Castellanous EJ, Kaneda Y, Nakashima Y, Shirasuna K, Sueishi K: Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor beta1, and tissue factor and also cell growth and invasion activities. Cancer Res. 2000, 60: 6531-6.PubMed
76.
Abdelrahim M, Samudio I, Smith R, Burghardt R, Safe S: Small inhibitory RNA duplexes for Sp1 mRNA block basal and estrogen-induced gene expression and cell cycle progression in MCF-7 breast cancer cells. J Biol Chem. 2002, 277: 28815-22. 10.1074/jbc.M203828200.CrossRefPubMed
77.
Chang DJ, Paik YK, Leren TP, Walker DW, Howlett GJ, Taylor JM: Characterization of a human apolipoprotein E gene enhancer element and its associated protein factors. J Biol Chem. 1990, 265: 9496-504.PubMed
78.
Ferreira S, Dupire MJ, Delacourte A, Najib J, Caillet-Boudin ML: Synthesis and regulation of apolipoprotein E during the differentiation of human neuronal precursor NT2/D1 cells into postmitotic neurons. Exp Neurol. 2000, 166: 415-21. 10.1006/exnr.2000.7510.CrossRefPubMed
79.
Horsburgh K, Nicoll JA: Selective alterations in the cellular distribution of apolipoprotein E immunoreactivity following transient cerebral ischaemia in the rat. Neuropathol Appl Neurobiol. 1996, 22: 342-349. 10.1111/j.1365-2990.1996.tb01113.x.CrossRefPubMed
80.
Boschert U, Merlo-Pich E, Higgins G, Roses AD, Catsicas S: Apolipoprotein E expression by neurons surviving excitotoxic stress. Neurobiol Dis. 1999, 6: 508-514. 10.1006/nbdi.1999.0251.CrossRefPubMed
81.
Barger SW, DeWall KM, Liu L, Mrak RE, Griffin WS: Relationships between expression of apolipoprotein E and beta-amyloid precursor protein are altered in proximity to Alzheimer beta-amyloid plaques: potential explanations from cell culture studies. J Neuropathol Exp Neurol. 2008, 67: 773-783. 10.1101/lm.1112209.PubMedCentralCrossRefPubMed
82.
Jones PL, Ping D, Boss JM: Tumor necrosis factor a and interleukin-1b regulate the murine manganese superoxide dismutase gene through a complex intronic enhancer involving C/EBP-b and NF-kB. Mol Cell Biol. 1997, 17: 6970-81.PubMedCentralCrossRefPubMed
83.
Xu Y, Kiningham KK, Devalaraja MN, Yeh CC, Majima H, Kasarskis EJ, St Clair DK: An intronic NF-kappaB element is essential for induction of the human manganese superoxide dismutase gene by tumor necrosis factor-alpha and interleukin-1beta. DNA Cell Biol. 1999, 18: 709-22. 10.1089/104454999314999.CrossRefPubMed
84.
Grilli M, Goffi F, Memo M, Spano P: Interleukin-1b and glutamate activate the NF-kB/Rel binding site from the regulatory region of the amyloid precursor protein gene in primary neuronal cultures. J Biol Chem. 1996, 271: 15002-15007. 10.1074/jbc.271.25.15002.CrossRefPubMed
85.
Bernardo A, Levi G, Minghetti L: Role of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and its natural ligand 15-deoxy-Delta12, 14-prostaglandin J2 in the regulation of microglial functions. Eur J Neurosci. 2000, 12: 2215-23. 10.1046/j.1460-9568.2000.00110.x.CrossRefPubMed
86.
Cernuda-Morollon E, Rodriguez-Pascual F, Klatt P, Lamas S, Perez-Sala D: PPAR agonists amplify iNOS expression while inhibiting NF-kappaB: implications for mesangial cell activation by cytokines. J Am Soc Nephrol. 2002, 13: 2223-31. 10.1097/01.ASN.0000025786.87646.B1.CrossRefPubMed
87.
Yang L, Tao LY, Chen XP: Roles of NF-kappaB in central nervous system damage and repair. Neurosci Bull. 2007, 23: 307-13. 10.1007/s12264-007-0046-6.CrossRefPubMed
88.
Sarnico I, Lanzillotta A, Boroni F, Benarese M, Alghisi M, Schwaninger M, Inta I, Battistin L, Spano P, Pizzi M: NF-kappaB p50/RelA and c-Rel-containing dimers: opposite regulators of neuron vulnerability to ischaemia. J Neurochem. 2009, 108: 475-85. 10.1111/j.1471-4159.2008.05783.x.CrossRefPubMed
89.
Oeth P, Mackman N: Salicylates inhibit lipopolysaccharide-induced transcriptional activation of the tissue factor gene in human monocytic cells. Blood. 1995, 86: 4144-52.PubMed
90.
Jiang H, Sha SH, Schacht J: NF-kappaB pathway protects cochlear hair cells from aminoglycoside-induced ototoxicity. J Neurosci Res. 2005, 79: 644-51. 10.1002/jnr.20392.CrossRefPubMed
91.
Zhao X, Zhang Y, Strong R, Grotta JC, Aronowski J: 15d-Prostaglandin J2 activates peroxisome proliferator-activated receptor-gamma, promotes expression of catalase, and reduces inflammation, behavioral dysfunction, and neuronal loss after intracerebral hemorrhage in rats. J Cereb Blood Flow Metab. 2006, 26: 811-20. 10.1038/sj.jcbfm.9600233.CrossRefPubMed
92.
Zheng L, Howell SJ, Hatala DA, Huang K, Kern TS: Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes. 2007, 56: 337-45. 10.2337/db06-0789.CrossRefPubMed
93.
Kerr BJ, Girolami EI, Ghasemlou N, Jeong SY, David S: The protective effects of 15-deoxy-delta-(12,14)-prostaglandin J2 in spinal cord injury. Glia. 2008, 56: 436-48. 10.1002/glia.20630.CrossRefPubMed
94.
Sarnico I, Boroni F, Benarese M, Alghisi M, Valerio A, Battistin L, Spano P, Pizzi M: Targeting IKK2 by pharmacological inhibitor AS602868 prevents excitotoxic injury to neurons and oligodendrocytes. J Neural Transm. 2008, 115: 693-701. 10.1007/s00702-007-0016-1.CrossRefPubMed
95.
Zheng H, Jiang M, Trumbauer ME, Sirinathsinghji DJ, Hopkins R, Smith DW, Heavens RP, Dawson GR, Boyce S, Conner MW, Stevens KA, Slunt HH, Sisoda SS, Chen HY, Ploeg Van der LH: β-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell. 1995, 81: 525-31. 10.1016/0092-8674(95)90073-X.CrossRefPubMed
96.
97.
Roses AD, Gilbert J, Xu PT, Sullivan P, Popko B, Burkhart DS, Christian-Rothrock T, Saunders AM, Maeda N, Schmechel DE: Cis-acting human ApoE tissue expression element is associated with human pattern of intraneuronal ApoE in transgenic mice. Neurobiol Aging. 1998, 19: S53-8. 10.1016/S0197-4580(98)00030-X.CrossRefPubMed
Metadata
Title
Unique aspects of transcriptional regulation in neurons – nuances in NFκB and Sp1-related factors
Authors
Xianrong R Mao
Andréa M Moerman-Herzog
Yuzhi Chen
Steven W Barger
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2009
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/1742-2094-6-16

Other articles of this Issue 1/2009

Journal of Neuroinflammation 1/2009 Go to the issue

Research

Absence of the complement regulatory molecule CD59a leads to exacerbated neuropathology after traumatic brain injury in mice

Research

Cellular immune response to intrastriatally implanted allogeneic bone marrow stromal cells in a rat model of Parkinson's disease

Research

Microglial inhibition of neuroprotection by antagonists of the EP1 prostaglandin E2 receptor

Short report

Resveratrol inhibits prostaglandin formation in IL-1β-stimulated SK-N-SH neuronal cells

Research

Effects of the PPAR-β agonist GW501516 in an in vitro model of brain inflammation and antibody-induced demyelination

Research

Cellular injury and neuroinflammation in children with chronic intractable epilepsy